Special Use-results Survery of Rituxan Intravenous Injection - Relapse Prevention of Neuromyelitis Optica Spectrum Disorder (including Neuromyelitis Optica) -

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220487

Enrollment

200

Registered

2022-12-04

Start date

2022-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuromyelitis optica spectrum disorder (including neuromyelitis optica)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have received Rituxan intravenous injection for relapse prevention of neuromyelitis optica spectrum disorder (including neuromyelitis optica)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Incidence of adverse drug reactions and severe adverse events (including grade 3/4 laboratory abnormalities)	—

Contacts

Public ContactJunko Sakamoto

Zenyaku Kogyo, Co., LTD.

Junko_Sakamoto@mail.zenyaku.co.jp+81-339461136

Outcome results